Cyta Therapeutics is a pre-clinical company developing therapies for cardiometabolic diseases. Cyta’s lead clinical candidate is a liver targeted nanoparticle encapsulating a thyromimetic for the treatment of obesity and other cardiometabolic syndromes. Cyta’s lead clinical candidate has demonstrated 28% weight loss in the diet-induced obesity-NASH (DIO-NASH) mouse model. Results also showed lowered cholesterol and triglycerides, reduction of fatty liver/steatosis and improvement of insulin sensitivity. There was no lowering of T4 levels suggesting no peripheral side effects due to the liver targeting of the nanoparticle delivery system. Short-term (1 month) toxicity studies have not generated any safety concerns. Cyta 's lead clinical candidate is two years away from IND submission. The company was co-founded by Professor Thayumanavan of UMass, Amherst, CEO, Bonnie Fendrock, MS, MBA, a biotech leader (Genzyme), and entrepreneur (Hepregen), and CSO, Steve Faraci, PhD, a pharmaceutical development leader (Pfizer). Cyta has filed IP on the lead clinical candidate and has an exclusive option to the platform delivery technology developed by Professor Thayumanavan.